GlassScriptPhysician profile
Karl C Golnik
NPI 1407896871
$15,410.57
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,511 · 2020: $22.29 · 2021: $3,127 · 2022: $2,403 · 2023: $4,333 · 2024: $14.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,685 · Travel and Lodging: $418 · Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,685.00 |
| Travel and Lodging | $417.51 |
| Food and Beverage | $245.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $9,853.85 | 2019-2023 | Soliris |
| Horizon Therapeutics Plc | $5,298.79 | 2019-2022 | |
| Biotissue Holdings INC. | $46.69 | 2022-2023 | |
| Allergan, INC. | $46.28 | 2021 | |
| Mallinckrodt Hospital Products INC. | $35.79 | 2023 | Acthar |
| Sun Pharmaceutical Industries INC. | $33.61 | 2021-2022 | |
| Alcon Vision LLC | $31.34 | 2019-2022 | |
| Argenx US, INC. | $27.47 | 2023 | Vyvgart |
| Aerie Pharmaceuticals, INC. | $22.29 | 2020 | |
| Amgen INC. | $14.46 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Golnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.